Trandolapril
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Trandolapril: From Hypertension to Malignant Renovascular Hypertension
One-Sentence Summary
Trandolapril is an ACE inhibitor whose established pharmacological class effect is blood pressure reduction in hypertension. The TxGNN model predicts a possible effect in Malignant Renovascular Hypertension, but this specific direction currently has 0 clinical trials and 0 publications supporting it — the signal is model-prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypertension (ACE inhibitor class; specific approved indication text not available in this pack) |
| Predicted New Indication | Malignant Renovascular Hypertension |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L5 |
| Denmark Market Status | Not Marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for trandolapril is not available in this pack. Based on the information provided, trandolapril belongs to the ACE inhibitor (ACEi) class, which inhibits conversion of angiotensin I to angiotensin II, lowering systemic vascular resistance and intraglomerular pressure. This is the shared mechanism by which ACEi-class drugs treat hypertension, including some forms of renovascular hypertension.
However, the predicted indication combines “malignant” (accelerated, end-organ-damaging) hypertension with “renovascular” disease, which — particularly when bilateral renal artery stenosis is present — is a relative contraindication or high-risk setting for ACE inhibitors, since these agents can precipitate acute kidney injury in that context. In other words, the underlying mechanism supports blood-pressure lowering in general, but it does not by itself support safe use in this specific severe subtype.
This prediction should therefore be read as a pharmacological class-level extrapolation by the TxGNN model rather than as evidence of safety or efficacy in the malignant renovascular subgroup specifically.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Denmark Market Information
Trandolapril currently has no registered marketing authorisation in Denmark (0 authorisations; market status: Not Marketed).
Safety Considerations
Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a general ACEi class-level mechanistic rationale (L5, model prediction only), with no clinical trials or literature identified for this specific indication. Additionally, the malignant renovascular subtype carries a plausible safety concern (risk of acute kidney injury) that argues against proceeding without further data.
To proceed, the following is needed:
- Danish/EU SmPC warnings, precautions and contraindications for trandolapril (currently a blocking data gap)
- Confirmed mechanism of action data from DrugBank or equivalent source
- Targeted literature/clinical search specific to renovascular or malignant hypertension subgroups, ideally addressing renal artery stenosis risk
- Renal function and blood pressure monitoring plan if any future evaluation proceeds
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.